{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:07:28Z","timestamp":1790255248488,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018283","name":"Eagles Fifth District Cancer Telethon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018283","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001172","name":"Hormel Foundation Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001172","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA285620"],"award-info":[{"award-number":["R01CA285620"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201282","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:46:36Z","timestamp":1782517596000},"page":"201282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Federica","family":"Ghersa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Yung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisae","family":"Kuoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Caine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Krotova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Borgatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2726-8627","authenticated-orcid":false,"given":"George","family":"Aslanidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201282_bib1","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1089\/hum.2024.114","article-title":"Adeno-Associated Virus Vectors-a Target of Cellular and Humoral Immunity-are Expanding Their Reach Toward Hematopoietic Stem Cell Modification and Immunotherapies","volume":"35","author":"Araujo","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201282_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.999021","article-title":"Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood","volume":"13","author":"Smith","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201282_bib3","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Costa Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib5","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3389\/fimmu.2020.00670","article-title":"Human Immune Responses to Adeno-Associated Virus (AAV) Vectors","volume":"11","author":"Ronzitti","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201282_bib6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.omton.2026.201282_bib7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omton.2026.201282_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.753467","article-title":"Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog","volume":"12","author":"Rapti","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201282_bib9","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.7150\/thno.89380","article-title":"Understanding AAV vector immunogenicity: from particle to patient","volume":"14","author":"Dhungel","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.omton.2026.201282_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.00730-25","article-title":"Teaching an old vector new tricks: the surprising versatility of AAV vaccines","volume":"99","author":"Winston","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.omton.2026.201282_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117010","article-title":"Adeno-associated viral vectors deliver gene vaccines","volume":"281","author":"Wei","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.omton.2026.201282_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101418","article-title":"A novel platform for engineered AAV-based vaccines","volume":"33","author":"Babutzka","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70447","article-title":"Revolution of AAV in Drug Discovery: From Delivery System to Clinical Application","volume":"97","author":"Yin","year":"2025","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.omton.2026.201282_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.omto.2018.12.004","article-title":"Recombinant AAV-CEA Tumor Vaccine in Combination with an Immune Adjuvant Breaks Tolerance and Provides Protective Immunity","volume":"12","author":"Hensel","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201282_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omtm.2023.03.010","article-title":"Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy","volume":"29","author":"Franke","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.omto.2019.10.001","article-title":"An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation","volume":"15","author":"Krotova","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201282_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.omtm.2023.01.006","article-title":"Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model","volume":"28","author":"Krotova","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib18","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.omtm.2023.02.009","article-title":"On the way to developing AAV-based vaccines as novel tools for cancer immunotherapy","volume":"28","author":"Hacker","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib19","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1016\/j.ymthe.2025.07.014","article-title":"Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles","volume":"33","author":"Neukirch","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/2326-6066.CIR-22-0318","article-title":"A Novel Engineered AAV-Based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors","volume":"11","author":"Huang","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2026.201282_bib21","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/mt.2012.260","article-title":"Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer","volume":"21","author":"Steel","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fimmu.2014.00005","article-title":"AAV Vectors Vaccines Against Infectious Diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201282_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors","volume":"12","author":"B\u00fcning","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101358","article-title":"Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association","volume":"32","author":"Molina","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.immuni.2025.01.009","article-title":"In vivo engineering of murine T cells using the evolved adeno-associated virus variant Ark313","volume":"58","author":"Nyberg","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201282_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17122025","article-title":"The Role of Canine Models of Human Cancer: Overcoming Drug Resistance Through a Transdisciplinary \u201cOne Health, One Medicine\u201d Approach","volume":"17","author":"Gargiulo","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201282_bib27","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human cancer therapy through the evaluation of pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.omton.2026.201282_bib28","article-title":"Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs","volume":"7","author":"Wu","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.omton.2026.201282_bib29","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","article-title":"Dogs as a Model for Cancer","volume":"4","author":"Gardner","year":"2016","journal-title":"Annu. Rev. Anim. Biosci."},{"key":"10.1016\/j.omton.2026.201282_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/vco.12996","article-title":"Molecular and Pathobiology of Canine Mammary Tumour: Defining a Translational Model for Human Breast Cancer","volume":"22","author":"Oliveira-Lopes","year":"2024","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.omton.2026.201282_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/biology11010054","article-title":"Companion Animal Model in Translational Oncology; Feline Oral Squamous Cell Carcinoma and Canine Oral Melanoma","volume":"11","author":"Giuliano","year":"2021","journal-title":"Biology"},{"key":"10.1016\/j.omton.2026.201282_bib32","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molmed.2011.02.004","article-title":"Dog models of naturally occurring cancer","volume":"17","author":"Rowell","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.omton.2026.201282_bib33","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/09553002.2021.1987572","article-title":"Canine comparative oncology for translational radiation research","volume":"98","author":"Boss","year":"2022","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.omton.2026.201282_bib34","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41433-024-03578-0","article-title":"Canine Best disease as a translational model","volume":"39","author":"Aguirre","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.omton.2026.201282_bib35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ymthe.2005.08.008","article-title":"Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness","volume":"12","author":"Acland","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101205","article-title":"AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life","volume":"32","author":"Doshi","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.gt.3300548","article-title":"Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia","volume":"5","author":"Monahan","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201282_bib38","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"Mount","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omton.2026.201282_bib39","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/4751","article-title":"Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors","volume":"5","author":"Snyder","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201282_bib41","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/mt.2014.151","article-title":"Forelimb treatment in a large cohort of dystrophic dogs supports delivery of a recombinant AAV for exon skipping in Duchenne patients","volume":"22","author":"Le Guiner","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201282_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101268","article-title":"SERCA2a overexpression improves muscle function in a canine Duchenne muscular dystrophy model","volume":"32","author":"Kodippili","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omton.2026.201282_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100905","article-title":"Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer","volume":"2","author":"Rotolo","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omton.2026.201282_bib44","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1158\/1078-0432.CCR-16-0088","article-title":"Immunotherapy with a HER2-Targeting Listeria Induces HER2-Specific Immunity and Demonstrates Potential Therapeutic Effects in a Phase I Trial in Canine Osteosarcoma","volume":"22","author":"Mason","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2026.201282_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.100736","article-title":"Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma","volume":"31","author":"Makielski","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201282_bib46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/1535-7163.MCT-17-0432","article-title":"Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer","volume":"17","author":"Naik","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.omton.2026.201282_bib47","first-page":"56","article-title":"Bone marrow-derived dendritic cell vaccination of dogs with naturally occurring melanoma by using human gp100 antigen","volume":"19","author":"Gyorffy","year":"2005","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.omton.2026.201282_bib48","article-title":"Development of canine PD-1\/PD-L1 specific monoclonal antibodies and amplification of canine T cell function","volume":"15","author":"Choi","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201282_bib49","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/vru.12860","article-title":"Multimodality treatment including ONCEPT for canine oral melanoma: A retrospective analysis of 131 dogs","volume":"61","author":"Turek","year":"2020","journal-title":"Vet. Radiol. Ultrasound"},{"key":"10.1016\/j.omton.2026.201282_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1053\/j.ctsap.2007.03.004","article-title":"Canine oral melanoma","volume":"22","author":"Bergman","year":"2007","journal-title":"Clin. Tech. Small Anim. Pract."},{"key":"10.1016\/j.omton.2026.201282_bib51","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"\u015eahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201282_bib52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.2460\/javma.245.11.1266","article-title":"Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998-2011)","volume":"245","author":"Tuohy","year":"2014","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.omton.2026.201282_bib53","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s00262-019-02360-6","article-title":"Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy","volume":"68","author":"Tarone","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201282_bib54","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1177\/03009858211011939","article-title":"PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma","volume":"58","author":"Stevenson","year":"2021","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.omton.2026.201282_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.803093","article-title":"Canine Melanoma Immunology and Immunotherapy: Relevance of Translational Research","volume":"9","author":"Tarone","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib56","article-title":"Canine melanoma: A review of diagnostics and comparative mechanisms of disease and immunotolerance in the era of the immunotherapies","volume":"9","author":"Stevenson","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/genes10070501","article-title":"Canine Melanomas as Models for Human Melanomas: Clinical, Histological, and Genetic Comparison","volume":"10","author":"Prouteau","year":"2019","journal-title":"Genes"},{"key":"10.1016\/j.omton.2026.201282_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2026.201282_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030799","article-title":"Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy","volume":"19","author":"Barutello","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib60","article-title":"Single institution study of the immune landscape for canine oral melanoma based on transcriptome analysis of the primary tumor","volume":"10","author":"Vanhaezebrouck","year":"2023","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2024.1397518","article-title":"Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective","volume":"11","author":"Xia","year":"2024","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2026.201746","article-title":"The dose makes the poison: Mechanisms of cytotoxicity of high-dose AAV vectors","volume":"34","author":"Flotte","year":"2026","journal-title":"Mol. Ther. Adv."},{"key":"10.1016\/j.omton.2026.201282_bib63","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2026.201282_bib64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201282_bib65","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000369273","article-title":"Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer","volume":"7","author":"Rogers","year":"2015","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.omton.2026.201282_bib66","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/vco.12679","article-title":"Evaluation of prognostic impact of pre-treatment neutrophil to lymphocyte and lymphocyte to monocyte ratios in dogs with oral malignant melanoma treated with surgery and adjuvant CSPG4-antigen electrovaccination: an explorative study","volume":"19","author":"Camerino","year":"2021","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.omton.2026.201282_bib67","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/jsap.12613","article-title":"Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK","volume":"58","author":"Verganti","year":"2017","journal-title":"J. Small Anim. Pract."},{"key":"10.1016\/j.omton.2026.201282_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/vetsci9050196","article-title":"Treatment of Canine Oral Melanomas: A Critical Review of the Literature","volume":"9","author":"Pazzi","year":"2022","journal-title":"Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib69","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2460\/ajvr.72.12.1631","article-title":"Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor","volume":"72","author":"Grosenbaugh","year":"2011","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.omton.2026.201282_bib70","article-title":"Corrigendum: Melanoma of the dog and cat: consensus and guidelines","volume":"11","author":"Polton","year":"2024","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib71","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/vco.12057","article-title":"A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma","volume":"11","author":"Ottnod","year":"2013","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.omton.2026.201282_bib72","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1292\/jvms.15-0510","article-title":"A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma","volume":"78","author":"Treggiari","year":"2016","journal-title":"J. Vet. Med. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/vetsci9110597","article-title":"The Use of Oncept Melanoma Vaccine in Veterinary Patients: A Review of the Literature","volume":"9","author":"Pellin","year":"2022","journal-title":"Vet. Sci."},{"key":"10.1016\/j.omton.2026.201282_bib74","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4102\/jsava.v86i1.1246","article-title":"Use of the melanoma vaccine in 38 dogs: The South African experience","volume":"86","author":"McLean","year":"2015","journal-title":"J. S. Afr. Vet. Assoc."},{"key":"10.1016\/j.omton.2026.201282_bib75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2460\/javma.245.4.401","article-title":"Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001-2012)","volume":"245","author":"Boston","year":"2014","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.omton.2026.201282_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01652176.2025.2473717","article-title":"Clinical evaluation of HuDo-CSPG4 DNA electroporation as adjuvant treatment for canine oral malignant melanoma: comparison of two vaccination protocols","volume":"45","author":"Camerino","year":"2025","journal-title":"Vet. Q."},{"key":"10.1016\/j.omton.2026.201282_bib77","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/vco.12239","article-title":"Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination","volume":"15","author":"Piras","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.omton.2026.201282_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/vco.12690","article-title":"Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: A retrospective study on 155 cases","volume":"19","author":"Giacobino","year":"2021","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.omton.2026.201282_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004007","article-title":"Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial","volume":"10","author":"Riccardo","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2026.201282_bib80","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/07357908609017520","article-title":"Canine oral melanoma: comparison of surgery versus surgery plus Corynebacterium parvum","volume":"4","author":"MacEwen","year":"1986","journal-title":"Cancer Invest."},{"key":"10.1016\/j.omton.2026.201282_bib81","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0300985810390717","article-title":"Prognostic markers for canine melanocytic neoplasms: a comparative review of the literature and goals for future investigation","volume":"48","author":"Smedley","year":"2011","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.omton.2026.201282_bib82","doi-asserted-by":"crossref","first-page":"580","DOI":"10.2460\/javma.1981.178.06.580","article-title":"Prognostic criteria for dogs with oral melanoma","volume":"178","author":"Harvey","year":"1981","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.omton.2026.201282_bib83","series-title":"TNM Classification of Tumours in Domestic Animals","author":"Owen","year":"1980"},{"key":"10.1016\/j.omton.2026.201282_bib84","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1111\/liv.16065","article-title":"Drug-induced liver injury related to gene therapy: A new challenge to be managed","volume":"44","author":"Larrey","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.omton.2026.201282_bib85","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201282_bib86","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/jgm.1204","article-title":"Effective transduction by self-complementary adeno-associated viruses of human dendritic cells with no alteration of their natural characteristics","volume":"10","author":"Shin","year":"2008","journal-title":"J. Gene Med."},{"key":"10.1016\/j.omton.2026.201282_bib87","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/icb.2013.74","article-title":"Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy","volume":"92","author":"Pandya","year":"2014","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omton.2026.201282_bib88","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1089\/hum.2020.074","article-title":"Modifiers of Adeno-Associated Virus-Mediated Gene Expression in Implication for Serotype-Universal Neutralizing Antibody Assay","volume":"31","author":"Krotova","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201282_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020523","article-title":"Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans","volume":"11","author":"Kuoch","year":"2023","journal-title":"Biomedicines"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992600158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:41:21Z","timestamp":1790253681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992600158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S295032992600158X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201282","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201282"}}